A Phase 3 interventional study of Liposomal Bupivacaine and Ropivacaine in Abdominal Tumor, Postoperative Analgesia and Liposomal Bupivacaine, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-05-28.
Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Abdominal Neoplasms with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Abdominal Neoplasms · China.
Among the 10 studies in Abdominal Neoplasms with a site in China, this one is the only one that started in 2023, is the only one in phase 3, and was the 5th registered.
42 studies on the registry are indexed under Abdominal Neoplasms; 14 are open to participants now.
Browse Abdominal Neoplasms studies →5 of the 10 studies in Abdominal Neoplasms with a site in China are open now. Recruiting first, the newest first:
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 29 days–18 yrs
Xiangdong Cheng · Sites in China
Ages 18–75 · Healthy volunteers
Huazhong University of Science and Technology · Sites in China
Ages 18–85
Huazhong University of Science and Technology · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 8 Abdominal Neoplasms studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 74 is close to the median of 78 across 26 interventional studies indexed under Abdominal Neoplasms.
Median enrollment 150 across the 5 interventional studies, 108 across the 5 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 9 most frequent:
Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.
Sun Yat-sen University has 1 study filed under Abdominal Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Abdominal Neoplasms with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Few studies have compared the efficacy of ultrasound (US)-guided TAP blocks with Liposomal bupivacaine(LB) versus ropivacaine in reducing postoperative opioid usage in patients undergoing laparoscopic lower abdominal tumor Resection. Therefore, we are conducting this prospective, randomized controlled trial to compare the postoperative analgesic effects of LB and ropivacaine for TAP blocks among patients undergoing laparoscopic colorectal procedures.
This study aimed to investigate the impact of liposomal bupivacaine (LB) on postoperative opioid usage for ultrasound(US)-guided transversus abdominis plane (TAP) blocks in laparoscopic colorectal resections. We divided 76 patients into two groups. An injection of bilateral TAP blocks was administered to LB group using 133mg liposomal bupivacaine in each block (266mg total), and to R group using 20 ml 0.25% ropivacaine in each block (40 ml total). Opioid consumption and pain scores at 6h, 24h, 48h and 72h were recorded postoperatively, as well as the total intraoperative remifentanil dose, the hospital stay lengths after surgery, and adverse events including dizziness, nausea, and vomiting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liposomal Bupivacaine was used in the group
Drug: Liposomal Bupivacaine
Ropivacaine was used in this group
Drug: Ropivacaine
After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).
Also known as: Bupivacaine liposome
Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).
Also known as: Ropivacaine Hydrochloride Injection
Postoperative opioid use
The amount of drug used in the postoperative analgesia pump
Time frame: 3 days postoperatively
Postoperative pain score
Postoperative VAS score
Time frame: 3 days postoperatively
Postoperative adverse reactions
Postoperative adverse reactions were followed up
Time frame: 3 days postoperatively
Plan to share: Yes — https://www.medicalresearch.org.cn/,Time: After completing the academic paper for publication
Supporting information: Study protocol
Time frame: After completing the academic paper for publication
Access criteria: The persons who were willing to study.
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in May 2024, 6 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine